Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 756 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Renal Disease Clear all
Completed Not applicable Interventional Results available

The EvAluation of TaBlo In-CLinic and In-HOme

NCT02460263
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

NCT02729038
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Not applicable Interventional

Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study

NCT05927532
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Argyle Safety Fistula Cannula with Anti-Reflux Valve
Device
Lead sponsor
Mozarc Medical US LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Hartford, Connecticut • Columbus, Georgia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Not applicable Interventional

The "Step4Life" Randomized Control Trial in Hemodialysis

NCT05241171
View directory record Official record
Conditions
Physical Activity, End Stage Kidney Disease, Hemodialysis
Interventions
Fitbit
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 14, 2026, 8:28 PM EDT
Withdrawn No phase listed Observational

Taste And Smell TEsting in End Stage Renal Disease

NCT03043144
View directory record Official record
Conditions
Kidney Failure, Chronic, Olfaction Disorders, Taste Disorders, Malnutrition
Interventions
Worsening of olfaction from enrollment visit to 6 months, Worsening of taste from enrollment visit to 6 months, Serum Zinc, Chronic rhinosinusitis, Dialysis adequacy, Decayed missing filled teeth index (DMFT)
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

NCT01503021
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
SFP, Placebo
Drug · Other
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Mobile, Alabama • Northridge, California • Arvada, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597584
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin alfa or Epoetin beta
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 14, 2026, 8:28 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Empagliflozin in ESKD - A Feasibility Study

NCT05687058
View directory record Official record
Conditions
Kidney Failure, Chronic, Heart Failure
Interventions
Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 2 Interventional Results available

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

NCT04571619
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Pain, Opioid Dependence
Interventions
Pain Coping Skills Training (PCST), Buprenorphine
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Not applicable Interventional

Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation

NCT03189212
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Disease, Chronic
Interventions
Usual Care Visit, Telemedicine Visit
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Triferic Pediatric Pharmacokinetic Protocol

NCT02595437
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Not applicable Interventional Results available

Impact of Vitamin D Therapies on Chronic Kidney Disease

NCT01222234
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
Interventions
Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD
Drug · Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Not applicable Interventional Results available

Impact of Vitamin D Repletion in Hemodialysis Patients

NCT01175798
View directory record Official record
Conditions
Vitamin D Deficiency, End-stage Renal Disease
Interventions
Cholecalciferol
Drug
Lead sponsor
Mehrotra, Anita, M.D.
Individual
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 14, 2026, 8:28 PM EDT
Not listed Not applicable Interventional

Alio WEAR Study: Long-term Wear of the Alio Platform

NCT06056739
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Alio platform
Device
Lead sponsor
Alio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Huntley, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

NCT02674581
View directory record Official record
Conditions
HIV Infections
Interventions
Oral BMS-663068 (pro-drug)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 14, 2026, 8:28 PM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

NCT02486744
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Acthar Gel
Drug
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans

NCT00189202
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Transplantation
Interventions
Sirolimus
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 14, 2026, 8:28 PM EDT
Withdrawn Phase 4 Interventional

Spironolactone Safety in Dialysis Patients

NCT00328809
View directory record Official record
Conditions
End Stage Renal Disease, Congestive Heart Failure
Interventions
spironolactone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 2Phase 3 Interventional

Quality of Life Therapy for Adults With ESRD Awaiting Renal Transplantation

NCT00428012
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Quality of Life Therapy, Supportive Therapy
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Not applicable Interventional

Development of Fluid Intake App for Management of Fluid Intake During Hemodialysis , Full Scale Trial

NCT04194164
View directory record Official record
Conditions
Weight Gain
Interventions
Fluid intake app
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 2 Interventional

The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis

NCT00179179
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplementation, exercise
Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Not applicable Interventional Results available

Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients

NCT00420290
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
kineret, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

NCT07165015
View directory record Official record
Conditions
Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
Interventions
LY3537031
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Orlando, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 14, 2026, 8:28 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

NCT01146574
View directory record Official record
Conditions
Anemia
Interventions
Sotatercept, Placebo
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
24
States / cities
Azusa, California • Glendale, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 14, 2026, 8:28 PM EDT